News

Rutgers Researchers Determine the 3D Structure of Drug Target for Rifampin

Scientist at Rutgers University and their collaborators have published an article in Molecular Cell illustrating the three-dimensional structure of the drug target for the drug rifampicin. The abstract for the article is below. 

TITLE: Structural Basis of Mycobacterium tuberculosis Transcription and Transcription Inhibition

AUTHOR: Lin, Wei et al.

ABSTRACT:

Mycobacterium tuberculosis
 (Mtb) is the causative agent of tuberculosis, which kills 1.8 million annually. Mtb RNA polymerase (RNAP) is the target of the first-line antituberculosis drug rifampin (Rif). We report crystal structures of Mtb RNAP, alone and in complex with Rif, at 3.8–4.4 Å resolution. The results identify an Mtb-specific structural module of Mtb RNAP and establish that Rif functions by a steric-occlusion mechanism that prevents extension of RNA. We also report non-Rif-related compounds—Nα-aroyl-N-aryl-phenylalaninamides (AAPs)—that potently and selectively inhibit Mtb RNAP and Mtb growth, and we report crystal structures of Mtb RNAP in complex with AAPs. AAPs bind to a different site on Mtb RNAP than Rif, exhibit no cross-resistance with Rif, function additively when co-administered with Rif, and suppress resistance emergence when co-administered with Rif.

Related Links: 

More News
29 Nov 2018
On December 6, 2018, at 7AM EST, TREAT TB will host a capacity building webinar on community engagement in MDR-TB clinical trials. It will feature a presentation from Ezio Tavora dos Santos Filho, STREAM Community Engagement Coordinator from REDE-TB , followed by a question and answer session. The...
2 Oct 2018
The first ever U.N. General Assembly’s high-level meeting (UNHLM) on tuberculosis took place on Wednesday, September 26 in New York City. The U.N. delegation of countries agreed to ambitious targets including a commitment to finding 40 million undiagnosed cases of TB by the end of 2022 and...
18 Sep 2018
In an article written by Lucica Ditiu, Executive Director, Stop TB Partnership, and Jacqueline Huh, Head, Strategic Initiatives & Innovative Financing, Stop TB, the 'valleys of death' that hold back TB new tools innovation are discussed. These two valleys occur between new tool development and...